Zealand Pharma A/S (ZEAL)
- GlobeNewswire
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
Company announcement – No. 73 / 2021 Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: T
- GlobeNewswire
Total number of shares and voting rights in Zealand Pharma at November 30, 2021
Company announcement – No. 72 / 2021 Total number of shares and voting rights in Zealand Pharma at November 30, 2021 Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the
- GlobeNewswire
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021
Company announcement – No. 71 / 2021 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021 Copenhagen, DK and Boston, MA, November 29, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: Followi
